Substance / Medication

Ofloxacin

Overview

Active Ingredient
ofloxacin
RxNorm CUI
7623

Indications

Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: * Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS : Gram - positive bacteria : Gram - negative bacteria : Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS :

Labeler: A-S Medication SolutionsUpdated: 2026-01-23T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Ofloxacin Ophthalmic Solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see Warnings).

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

7 trials linked to this intervention

7
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis.
Duong Trinh, Brigden Joanna, Simon Schaaf H et al. · NEJM Evid · 2025
PMID: 39693627Meta-Analysis
Prophylactic fluoroquinolones in hematopoietic stem cell transplant recipients: A meta-analytic comparison of ciprofloxacin and levofloxacin.
Albalawi Mohammed A Hameed, Al-Sayaghi Khaled Mohammed, Hegazy Samya Mohamed et al. · Medicine (Baltimore) · 2025
PMID: 40355203Meta-AnalysisFull text (PMC)
Ciprofloxacin resistance in community and hospital-acquired urinary tract infections: a systematic review and meta-analysis from African population.
Kibwana Upendo O, Manyahi Joel, Sabas Deodatus M et al. · BMC Infect Dis · 2025
PMID: 41455903Meta-Analysis
Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
White Yasmine N, Solans Belen P, Denti Paolo et al. · Clin Infect Dis · 2024
PMID: 38340060Meta-AnalysisFull text (PMC)
Effectiveness and safety of Levofloxacin containing regimen in the treatment of Isoniazid mono-resistant pulmonary Tuberculosis: a systematic review.
Inbaraj Leeberk Raja, Shewade Hemant Deepak, Daniel Jefferson et al. · Front Med (Lausanne) · 2023
PMID: 37415768Meta-AnalysisFull text (PMC)
Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis.
Keikha Masoud, Askari Parvin, Ghazvini Kiarash et al. · J Glob Antimicrob Resist · 2022
PMID: 34788690Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ofloxacin (substance)
SNOMED CT
387551000
UMLS CUI
C0028902
RxNorm CUI
7623
Labeler
A-S Medication Solutions

Clinical Data

This intervention maps to 25 entities in the Healos knowledge graph.

20
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.